Back to Authors

Travers, Paul

https://orcid.org/0000-0003-3044-2013

Mayo Clinic

Division of Internal Medicine

Citations 2

Current opinion: functional dyspepsia
Olson, Caroline G. , Travers, Paul , Lacy, Brian E. , Olson, Caroline , Travers, Paul

Current Opinion in Gastroenterology | June 20, 2024 | Volume: 40 | Issue: 6 | Pages: 470-476

10.1097/mog.0000000000001045 Get It

Purpose of review Functional dyspepsia is a common gastrointestinal disease that is under-recognized and under-diagnosed. It is a complex disorder of gut–brain interaction with no FDA-approved treatment options. The purpose of this review is to highlight updates in the proposed pathophysiology and present new data regarding potential therapies for functional dyspepsia. Recent findings Alterations in the intestinal microbiome and integrity of the intestinal membrane may play a crucial role in the pathogenesis of functional dyspepsia. The low FODMAP diet, in addition to modulating the microbiome with antibiotics and probiotics, are targets for large future studies. Novel methods of delivery of gut–brain therapies have shown promising results, especially virtual reality. Summary The pathophysiology and management of functional dyspepsia is complex and there is still much unknown; however, continued research is identifying new targets for treatment. New and more targeted treatment options provide clinicians a variety of tools to offer patients with functional dyspepsia.
Irritable bowel syndrome – less irritable, or better treatments?
Travers, Paul , Lacy, Brian E. , Cangemi, David J. , Travers, Paul

Current Opinion in Gastroenterology | December 11, 2023 | Volume: 40 | Issue: 1 | Pages: 27-33

10.1097/mog.0000000000000987 Get It

Purpose of review Irritable bowel syndrome (IBS) is a chronic, often bothersome disorder of gut-brain interaction (DGBI) characterized by abdominal pain associated with a change in stool frequency and/or caliber. Recent advancements have improved our understanding of the underlying pathophysiology, thus opening new avenues for therapeutic intervention. The purpose of this review is to summarize the current literature regarding treatment modalities for IBS. Recent findings Altering the gut microbiome via probiotic and antibiotic administration, avoiding dietary triggers, and modulating the gut-brain axis have all proven efficacious for the management of IBS symptoms. Several gut-specific pharmacotherapies are approved for the treatment of IBS, many of which primarily address either diarrhea or constipation, although many patients remain symptomatic despite appropriate use. Brain-gut behavioral therapies (BGBTs) are increasingly used to treat symptoms of IBS, particularly in those who do not respond to traditional therapies. Virtual reality represents an exciting new approach to treating DGBIs, like IBS, though data are limited. Summary As our understanding of IBS continues to evolve, so should our therapeutic approach. Individualizing the therapeutic approach is of utmost importance.